about
DRAGO (KIAA0247), a new DNA damage-responsive, p53-inducible gene that cooperates with p53 as oncosuppressor. [Corrected]A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcomaFOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patientsWiring miRNAs to pathways: a topological approach to integrate miRNA and mRNA expression profilesAnalysis of differential miRNA expression in primary tumor and stroma of colorectal cancer patients.A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.Development of distamycin-related DNA binding anticancer drugs.Unique features of the mode of action of ET-743.Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study.IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer.New molecules and strategies in the field of anticancer agents.Application of RNA-Seq transcriptome analysis: CD151 is an Invasion/Migration target in all stages of epithelial ovarian cancer.Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer.Mechanism of action of trabectedin in desmoplastic small round cell tumor cells.MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.Effect of Aplidin in acute lymphoblastic leukaemia cells.Brostallicin (PNU-166196)--a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells.microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition.Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts.A systems biology approach to investigate the mechanism of action of trabectedin in a model of myelomonocytic leukemia.Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.The expression of the DeltaNp73beta isoform of p73 leads to tetraploidy.Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.Effects of inducible overexpression of DNp73alpha on cancer cell growth and response to treatment in vitro and in vivo.Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4.Alpha-bromoacryloyl derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity.Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical modelsNovel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.Glutathione influences c-Myc-induced apoptosis in M14 human melanoma cells.Mode of action of trabectedin in myxoid liposarcomas.MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities.Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy.Protection of Brain Injury by Amniotic Mesenchymal Stromal Cell-Secreted Metabolites.A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment.lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study.Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature.Analysis of gene expression in early-stage ovarian cancer.
P50
Q24339462-92868C89-5533-47B4-B4C3-176E8123F5DAQ28482357-EA10D45C-859E-4A1C-AF8D-11CE89F1E5EDQ33651605-B24A21F0-35AB-4C10-AB2E-E163F2688CF0Q33791204-3147ADB6-7957-4AEF-ACDE-7A35FAD4226CQ34025645-064AAC64-4199-46DF-B93F-34CC27D16F74Q34240949-EE8A1826-E05F-452A-873B-F9423877D434Q34481722-BDACA411-47E3-432B-805F-29EA0B4F909FQ34686690-867CBC36-97B0-47F4-A078-D6263EF4F0E9Q35595719-C218FFD5-FE9E-47E4-A436-D71153097504Q35735751-0CFB61CB-F9F0-41F3-A2B1-763995760E9BQ35768346-216F11BE-6B76-475E-85D5-C75F56E6D179Q35785330-B7DA0402-F81B-4DE7-8F45-4D00797D22D4Q35802653-6775D5CD-6112-48C5-8511-1482FAB28197Q36091016-B2C9B88D-79C6-4D85-B026-E2D162C5901FQ36272148-3A6CBF8D-717E-491F-A744-1621244D5CC7Q36381924-219EB61F-8355-4234-8D60-6272A436B9E9Q36648269-1D2FDA13-462A-4D84-8FF0-4185BD497D1DQ36671252-3C0D43ED-80DF-489D-873A-FED849F4711DQ37497239-57CA839E-DFF2-4A2F-8DD7-E5B9FE965A12Q38722106-9D83CAEA-D691-4B09-9855-DA94A17A27CDQ39065392-4E35DFA8-3C61-48A5-8CAC-4E365C8C4721Q39106004-2296E6DA-D659-4871-8269-E79664FED2D0Q39497253-CFC06110-9A82-40D7-B6C9-0F588D98F74FQ39917183-34B2BB1A-623B-49E3-924A-ADE8F9619E75Q40091165-A862BD88-DC4B-4C9F-8050-F3C1D8AD7BE9Q40426270-F7BB3D66-B6CB-4D57-BEAA-3B50B7FEF416Q40677359-02FD748B-F035-4652-A3B6-9E230B6A949BQ40949673-6377CE86-330F-4836-A66A-C598FF8A3744Q41524895-280983D3-508F-47C6-8419-7954B420EDFDQ42928532-5B543757-AE50-4F5F-9035-9422F1F0E7B6Q44133878-A41526A0-2140-48E9-ABC6-B3E383AC3F66Q45346605-C75A5386-3CBF-4220-BC23-514A1747DFC0Q45915221-D638003D-C739-497F-B441-4974C7D0611AQ47855902-D243AF6A-7E27-4CB7-8DEE-E1E323E1E81EQ48475882-DF0B53AE-C007-4328-9064-E7BA18170238Q50858313-40254A5B-7DAE-409D-AF44-CEC46C0F3B65Q50860695-A60D63F6-A861-4C18-A88C-C10E68FFD508Q53158418-4F95592E-813F-4FEF-87FB-E784D16A60BCQ53748896-CC811F1C-E0CC-4445-AD97-DCD9F73669EEQ54505137-6718B850-C31C-433B-B29C-7EF3A953B01A
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sergio Marchini
@ast
Sergio Marchini
@en
Sergio Marchini
@es
Sergio Marchini
@nl
type
label
Sergio Marchini
@ast
Sergio Marchini
@en
Sergio Marchini
@es
Sergio Marchini
@nl
prefLabel
Sergio Marchini
@ast
Sergio Marchini
@en
Sergio Marchini
@es
Sergio Marchini
@nl
P106
P1153
7004639961
P21
P31
P496
0000-0003-1783-7651